Proven efficacy in patients with wet AMD 1-3

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD).

MARINA and ANCHOR

HARBOR

Dosing and Safety

Resources

Resources for your patients.

LUCENTIS Direct

Simple, personalized ordering.

LUCENTIS Co-pay Card Program

Support for your patients with commercial insurance.

LUCENTIS Access Solutions

Access and reimbursement services for your patients.